Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
June 17 (Reuters) - Eli Lilly LLY.N will acquire Verve Therapeutics VERV.O for up to $1.3 billion, the companies said on Tuesday.
Verve is developing therapies targeting genes that regulate cholesterol in the liver.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Fed FOMC Preview: No Rate Cuts Become Consensus, Warsh Succession Imminent

Marvell vs. Broadcom: Who Is the More Worthy ASIC Leading Company?

Tesla Stock Forecast: How Much Will TSLA Stock Be Worth in 2030? Can It Hit $3,000?

SanDisk Earnings Preview: AI Storage Drives Performance Surge, Valuations and Risks Rise

Tradingkey






